このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

TREO腹部ステントグラフトシステムの承認後試験 (TREO PAS)

2026年11月10日 更新者:Bolton Medical

腎下腹部大動脈および大動脈腸骨動脈瘤患者におけるTREO腹部ステントグラフトシステム(P190015)の承認後研究

The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms.

調査の概要

状態

積極的、募集していない

詳細な説明

This is a prospective, multi-center, non-randomized, single-arm, post-market, non-interventional study of treatment with the TREO Abdominal Stent-Graft in subjects with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms. The study will include a minimum of 300 subjects treated with the TREO Abdominal Stent-Graft at up to 55 investigational sites in the US.

The primary objective is the collection of real world safety and effectiveness outcomes of the TREO Abdominal Stent-Graft System in an all-comers population eligible for the endovascular treatment of AAA in routine clinical practice, with emphasis on subjects that experience a device stent-strut or barb fracture.

研究の種類

介入

入学 (実際)

338

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Arizona
      • Phoenix、Arizona、アメリカ、85006
        • Vascular Surgery Specialists
      • Tucson、Arizona、アメリカ、85718
        • Pima Heart and Vascular
    • California
      • Fresno、California、アメリカ、93701
        • University of California, San Francisco-Fresno
      • La Jolla、California、アメリカ、92037
        • University of California, San Diego
      • San Diego、California、アメリカ、92161
        • VA San Diego
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • University of Colorado Anschutz
    • Connecticut
      • New Haven、Connecticut、アメリカ、06520
        • Yale University
    • District of Columbia
      • Washington D.C.、District of Columbia、アメリカ、20010
        • Medstar Washington Hospital Center
    • Florida
      • Gainesville、Florida、アメリカ、32610
        • University of Florida
      • Gainesville、Florida、アメリカ、32608
        • Malcom Randall VA Medical Center
      • Pensacola、Florida、アメリカ、32504
        • Coastal Vascular and Interventional
      • Tampa、Florida、アメリカ、33606
        • University of South Florida / Tampa General Hospital
    • Georgia
      • Atlanta、Georgia、アメリカ、30342
        • Northside Hospital
      • Atlanta、Georgia、アメリカ、30309
        • Piedmont Heart Institute
    • Iowa
      • Iowa City、Iowa、アメリカ、52242
        • University of Iowa Hospital and Clinic
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02114
        • Massachusetts General Hospital
      • Boston、Massachusetts、アメリカ、02111
        • Tufts Medical Center
    • Michigan
      • Bay City、Michigan、アメリカ、48708
        • McLaren Bay Region
      • Detroit、Michigan、アメリカ、48202
        • Henry Ford Hospital
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55407
        • Minneapolis Heart Institute Foundation
    • Missouri
      • St Louis、Missouri、アメリカ、63110
        • Barnes Jewish Hospital at Washington University
    • New Jersey
      • Hackensack、New Jersey、アメリカ、07601
        • Hackensack University Medical Center
      • New Brunswick、New Jersey、アメリカ、08901
        • Rutgers Robert Wood Johnson Medical Center
    • New York
      • New York、New York、アメリカ、10075
        • Lenox Hill Hospital / Northwell Health
      • Stony Brook、New York、アメリカ、11794-8191
        • Stony Brook Medical Center
      • Syracuse、New York、アメリカ、13210
        • SUNY Upstate Medical University
      • The Bronx、New York、アメリカ、10467
        • Montefiore Medical Center
    • North Carolina
      • Asheville、North Carolina、アメリカ、27607
        • Mission Health
      • Greenville、North Carolina、アメリカ、27834
        • East Carolina University
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Portland、Oregon、アメリカ、97239
        • Oregon Health and Science University
      • Portland、Oregon、アメリカ、97239
        • VA Portland Healthcare System
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19140
        • Temple University Hospital
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • University of Pittsburgh Medical Center
    • Tennessee
      • Kingsport、Tennessee、アメリカ、37660
        • Wellmont Cardiology Services
    • Texas
      • Austin、Texas、アメリカ、78756
        • St. David's Healthcare (Cardiothoracic and Vascular Surgeons)
    • Utah
      • Salt Lake City、Utah、アメリカ、84132
        • University of Utah Hospital
    • Virginia
      • Norfolk、Virginia、アメリカ、22042
        • Sentara Heart Hospital
      • Richmond、Virginia、アメリカ、23282
        • Virginia Commonwealth University
    • Wisconsin
      • Milwaukee、Wisconsin、アメリカ、53226
        • Medical College of Wisconsin

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Willing and able to comply with all study procedures and visits.
  • Written informed consent to participate in the study.
  • Patient's aneurysm can be treated with the TREO Abdominal Stent-Graft System.
  • Adequate data (medical records/imaging studies) available to analyze the primary endpoints for patients enrolled retrospectively.

Exclusion Criteria:

• Medical, social or psychological problems that, in the opinion of the investigator, preclude patient from receiving treatment with the TREO Abdominal Stent-Graft System.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Subjects who receive the TREO Abdominal Stent-Graft System

Eligible subjects will be implanted with the TREO Abdominal Stent-Graft System.

The TREO Abdominal Stent-Graft System is intended for the treatment of infrarenal abdominal aortic aneurysms with or without iliac involvement.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of stent-strut fracture or barb separation as confirmed by the Imaging Core Laboratory.
時間枠:Through 5 Years post-procedure

Incidence of fracture in a stent-strut or separation of one or more proximal fixation barbs as confirmed by the Imaging Core Laboratory upon review of post-implant imaging studies.

Through 5 Years post-procedure
Incidence of secondary intervention for adverse events related to or caused as a result of stent-strut fracture or barb separation.
時間枠:Through 5 Years post-procedure

Incidence of secondary intervention for adverse events related to or caused as a result of a fracture in a stent-strut or separation of one or more proximal fixation barbs. Relatedness to the device will be confirmed by the Clinical Events Committee (CEC) through review of available treatment and procedure records and reports of imaging studies.

Through 5 Years post-procedure

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of participants with technical success at the conclusion of the index procedure
時間枠:Through 5 Years post-procedure

Defined as the following:

  • successful delivery (i.e., ability to deliver the implant to the intended location without the need for unanticipated corrective intervention related to delivery);
  • successful and accurate deployment (deployment of the endovascular stent graft in the planned location; patency of the endovascular stent graft, absence of device deformations such as kinks, stent eversion, mal-deployment, misaligned deployment, requiring unplanned placement of an additional device within the endovascular stent graft, and
  • successful withdrawal (i.e. successful withdrawal of the delivery system, without the need for unanticipated corrective intervention related to withdrawal)
Through 5 Years post-procedure
Major Adverse Events
時間枠:Through 5 Years post-procedure

Incidence of the following Major Adverse Events

  • Myocardial infarction according to SCAI definition
  • Stroke according to the VARC-2 guidelines
  • New Onset Renal Failure requiring permanent dialysis
  • New onset Respiratory Failure requiring permanent home oxygen therapy through 30 days
  • Permanent Paralysis/Paraplegia
  • Bowel Ischemia
  • Procedural blood loss (≥ 1000cc)
Through 5 Years post-procedure
Incidence of procedure-related clinical utility measures
時間枠:Through 5 Years post-procedure

Reporting of procedural data collected during implant of the TREO Abdominal Stent-Graft System including: Procedure time (minutes), Fluoroscopy time (minutes), Contrast volume (mL), Access method (i.e. percutaneous, surgical cut down), Length of ICU stay (hours), Length of hospital stay post-procedure (days), Anesthesia Type.

Through 5 Years post-procedure
Incidence of procedure-related complications
時間枠:Through 5 Years post-procedure

Incidence of adverse events occurring during or following the implant determined by the CEC to be procedure-related.

Through 5 Years post-procedure
Incidence of successful aneurysm treatment
時間枠:12 months post-implant

Successful aneurysm treatment is defined as:

  • Technical success
  • Absence of death from the initial procedure, secondary intervention or aortic-related cause.
  • Absence of persistent type I or III endoleaks
  • Absence of aneurysm sac expansion >5 mm
  • Absence of device migration >10mm
  • Absence of failure due to device integrity issues
  • Absence of aneurysm rupture
  • Absence of conversion to open surgical repair
  • Absence of permanent paraplegia, disabling stroke or dialysis that resulted from the initial operation or a secondary intervention to treat the original aortic pathology.
12 months post-implant
Incidence of all-cause mortality
時間枠:Through 5 Years post-procedure

Rate of mortality attributed to any causality as confirmed by the CEC.

Through 5 Years post-procedure
Incidence of aneurysm-related mortality
時間枠:Through 5 Years post-procedure

Rate of mortality attributed to the following causes as confirmed by the CEC: death due to a rupture, death within 30 days or prior to hospital discharge from primary procedure, or death within 30 days or prior to hospital discharge for a secondary procedure designed to treat the original aneurysm.

Through 5 Years post-procedure
Incidence of aneurysm rupture
時間枠:Through 5 Years post-procedure

Incidence of rupture of the native aneurysm sac post-implantation of the endograft as confirmed by the CEC.

Through 5 Years post-procedure
Incidence of secondary interventions.
時間枠:Through 5 Years post-procedure

Incidence of secondary procedures designed to treat or repair the original aneurysm treated with the TREO Abdominal Stent-Graft System

Through 5 Years post-procedure
Incidence of conversion to open surgical repair.
時間枠:Through 5 Years post-procedure

Incidence of conversion to open surgical AAA repair during the initial EVAR procedure secondary to any procedure-related complications as determined by the CEC.

Through 5 Years post-procedure
Incidence of stent-graft occlusion (i.e., loss of patency)
時間枠:Through 5 Years post-procedure

Incidence of stent-graft occlusion defined as the unintentional obstruction of the vascular/endograft lumen with minor obstruction (0-25%), minimal obstruction (26-74%), moderate obstruction (75-99%) or occlusion (100%) as confirmed by the Imaging Core Lab due to causes such as twisting or kinking of the prosthesis, oversizing and fabric pleating, or failure of the implant to fully open, or to mural thrombus deposition.

Through 5 Years post-procedure
Incidence of device stenosis or kink
時間枠:Through 5 Years post-procedure

Incidence of stenosis or kinking of the TREO Stent-Graft as confirmed by the Imaging Core Lab.

Through 5 Years post-procedure
Incidence of loss of device integrity
時間枠:Through 5 Years post-procedure

Incidence of changes in the structural integrity in a material component of the stent-graft such as a stent-strut fracture or separation of the proximal fixation barbs as confirmed by the Imaging Core Lab.

Through 5 Years post-procedure
Incidence of aneurysm enlargement (>5mm as compared to 30-day imaging).
時間枠:Through 5 Years post-procedure

Incidence of the increase in the aneurysm sac diameter > 5 mm at post-implant follow-up visits relative to the diameter determined at the first post-procedural imaging study, as confirmed by the Imaging Core Lab.

Through 5 Years post-procedure
Incidence of stent-graft migration (>10mm as compared to 30-day imaging)
時間枠:Through 5 Years post-procedure

Incidence of the longitudinal movement of all or part of a stent or attachment system for a distance of >10 mm relative to anatomical landmarks that were determined at the first post-procedural imaging study as confirmed by the Imaging Core Lab.

Through 5 Years post-procedure
Incidence of Type I, II, III, IV or V Endoleaks
時間枠:Through 5 Years post-procedure

Incidence of Type I, II, III, IV or V Endoleaks defined as the persistence of blood flow outside the lumen of the stent-graft but within the native aorta or adjacent vascular segment being treated by the stent-graft as determined by the Imaging Core Lab.

Through 5 Years post-procedure

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Gretchen Wild、Terumo Aortic

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年1月20日

一次修了 (推定)

2028年10月31日

研究の完了 (推定)

2028年10月31日

試験登録日

最初に提出

2020年12月10日

QC基準を満たした最初の提出物

2021年1月5日

最初の投稿 (実際)

2021年1月6日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月13日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • IP-0021-20

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する